@article{3003178,
    title = "Immunotherapy for gastric cancer: A 2021 update",
    author = "Kole, C. and Charalampakis, N. and Tsakatikas, S. and Kouris, N.-I. and Papaxoinis, G. and Karamouzis, M.V. and Koumarianou, A. and Schizas, D.",
    journal = "Journal of Immunotherapy",
    year = "2022",
    volume = "14",
    number = "1",
    pages = "41-64",
    publisher = "Future Medicine Ltd",
    issn = "1524-9557",
    doi = "10.2217/imt-2021-0103",
    abstract = "Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer are diagnosed at advanced stages, they are not suitable for surgery and present with locally advanced or metastatic disease. Recent advances in immunotherapy have elicited a considerable amount of attention as viable therapeutic options for several cancer types. This work presents a summary of the currently ongoing clinical trials and critically addresses the efficacy of a large spectrum of immunotherapy approaches in the general population for gastric cancer as well as in relation to tumor genetic profiling. © 2021 Future Medicine Ltd."
}